Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of ...
Acelyrin (SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a ...
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback